CL2004000579A1 - Uso de dienogest para preparar composiciones farmaceuticas destinadas a reducir el cuerpo de la glandula mamaria. - Google Patents

Uso de dienogest para preparar composiciones farmaceuticas destinadas a reducir el cuerpo de la glandula mamaria.

Info

Publication number
CL2004000579A1
CL2004000579A1 CL200400579A CL2004000579A CL2004000579A1 CL 2004000579 A1 CL2004000579 A1 CL 2004000579A1 CL 200400579 A CL200400579 A CL 200400579A CL 2004000579 A CL2004000579 A CL 2004000579A CL 2004000579 A1 CL2004000579 A1 CL 2004000579A1
Authority
CL
Chile
Prior art keywords
dienogest
reduce
pharmaceutical compositions
mammary gland
compositions intended
Prior art date
Application number
CL200400579A
Other languages
English (en)
Inventor
Claudia Moore
Michael Oettel
Andreas Muller
Eduard Schindler
Bernd Christensen
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7899230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2004000579(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of CL2004000579A1 publication Critical patent/CL2004000579A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

USO DE DIONEGEST EN UNA DOSIS DE POR LO MENOS 10mg, QUE SIRVE PARA GENERAR COMPOSICIONES FARMACEUTICAS DESTINADAS A REDUCIR EL CUERPO DE LA GLANDULA MAMARIA DICHAS COMPOSICIONES FARMACEUTICAS SIRVEN PARA REDUCIR EL CUERPO DE LA GLANDULA MAMARIA QUE CONTIENEN DIENOGEST EN UNA DOSIS DE AL MENOS 10mg CONJUNTAMENTE CON EXCIPIENTES, VEHICULOS Y/O ADITIVOS FARMACEUTICAMENTE ACEPTABLES. ENVASE FARMACEUTICO QUE CONTIENE VARIAS UNIDADES DE DOSIS DIARIAS DE DIENOGEST.
CL200400579A 1999-02-18 2004-03-19 Uso de dienogest para preparar composiciones farmaceuticas destinadas a reducir el cuerpo de la glandula mamaria. CL2004000579A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19908762A DE19908762A1 (de) 1999-02-18 1999-02-18 Verwendung von Dienogest in hoher Dosierung

Publications (1)

Publication Number Publication Date
CL2004000579A1 true CL2004000579A1 (es) 2005-01-07

Family

ID=7899230

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400579A CL2004000579A1 (es) 1999-02-18 2004-03-19 Uso de dienogest para preparar composiciones farmaceuticas destinadas a reducir el cuerpo de la glandula mamaria.

Country Status (12)

Country Link
US (1) US6670350B1 (es)
EP (1) EP1150683B9 (es)
JP (1) JP4233766B2 (es)
AT (1) ATE251459T1 (es)
AU (1) AU2802700A (es)
CA (1) CA2368370C (es)
CL (1) CL2004000579A1 (es)
DE (2) DE19908762A1 (es)
DK (1) DK1150683T3 (es)
ES (1) ES2208278T3 (es)
PT (1) PT1150683E (es)
WO (1) WO2000048604A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004019743B4 (de) * 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
US8153616B2 (en) * 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (de) * 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1593515C3 (de) * 1966-08-11 1975-08-14 Schering Ag, 1000 Berlin Und 4619 Bergkamen 6-Chlor-21 -fluor-1,2alpha-methylen-DeKa hoch 4,6 -pregnadiene, Verfahren zu deren Herstellung sowie diese enthaltende Mittel
FR2515041A1 (fr) * 1981-10-26 1983-04-29 Besins Jean Medicament a base de progesterone pour le traitement des affections mammaires
ATE215826T1 (de) * 1993-11-19 2002-04-15 Jenapharm Gmbh Karzinostatisches mittel für hormontherapie, das dienogest als wirksamer bestandteil enthält
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder

Also Published As

Publication number Publication date
WO2000048604A1 (de) 2000-08-24
EP1150683A1 (de) 2001-11-07
DK1150683T3 (da) 2004-02-09
EP1150683B9 (de) 2004-01-14
DE50003993D1 (de) 2003-11-13
CA2368370A1 (en) 2000-08-24
CA2368370C (en) 2008-05-06
ES2208278T3 (es) 2004-06-16
PT1150683E (pt) 2004-03-31
DE19908762A1 (de) 2000-08-31
AU2802700A (en) 2000-09-04
US6670350B1 (en) 2003-12-30
JP2002537261A (ja) 2002-11-05
JP4233766B2 (ja) 2009-03-04
EP1150683B1 (de) 2003-10-08
ATE251459T1 (de) 2003-10-15

Similar Documents

Publication Publication Date Title
CO5271697A1 (es) Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
ES2190472T3 (es) Parche transdermico para la administracion de 17-deacetil norgestimato, solo o en combinacion con un estrogeno.
BR0107869A (pt) Composições farmacêuticas eletrogiradas
HRP20070188A2 (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
ES2170503T3 (es) Composicion y metodo para tratar la disfuncion erectil del pene.
PE9899A1 (es) Progesterona para tratar o reducir isquemia
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
AP1849A (en) Dosage regimen and pharmaceutical composition for emergency contraception
CA2468748A1 (en) Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
YU53402A (sh) Preparat
BR0114665A (pt) Uso de antiprogestinas para a profilaxia e tratamento de doenças dependentes de hormÈnio
MX173567B (es) Procedimiento para preparar una composicion farmaceutica y composicion farmaceutica para mejorar los sintomas de enfermedad inducida por vih o reducir la transcripcion y proliferacion del vih
AR010538A1 (es) Composicion farmaceutica para inhibir el desarrollo del cancer de mama en mujeres menopausicas que comprende raloxifeno (6-[hidroxi]-2-(4-hidroxifenil)-benzo (b)-tien-3-il]-4-[-2-(1-piperidinil)etoxi-fenil)]-metanona
BR0010709A (pt) Gonadotrofinas
ES2108240T3 (es) Derivados de tiosemicarbazona de 2-formilpiridina, su preparacion y su uso como agentes antitumor.
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
CL2004000579A1 (es) Uso de dienogest para preparar composiciones farmaceuticas destinadas a reducir el cuerpo de la glandula mamaria.
CO5150233A1 (es) Formulacion de liberacion controlada para administrar un inhibidor de pde4
BR0214798A (pt) Uso de anastrozol ou um sal farmaceuticamente aceitável do mesmo, e, métodos para reduzir a taxa de recorrência de câncer e a taxa de um novo tumor primário contralateral em uma mulher pós-menopausa tendo câncer de mama em estado inicial
PE20020466A1 (es) Combinacion de raloxifeno y exemestano para el tratamiento de cancer de mama
MXPA05012841A (es) Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas.
WO2001051055A3 (en) Pharmaceutical compositions containing steroidal structures and uses thereof
RS50350B (sr) Upotreba 11beta-(4-acetilfenil)-17beta-hidroksi-17alfa-(1,1,2,2,2-pentafluoretil)estra-4,9-dien-3-ona za pripremanje medikamenta za lečenje kancera dojke, jajnika, endometrijuma, mijeloma i meningioma
Ginckel et al. Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7, 12-dimethylbenz (a) anthracene-induced mammary carcinoma in the rat
PE20020520A1 (es) Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas